# A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

> **NCT05975905** · PHASE2 · COMPLETED · sponsor: **Keros Therapeutics, Inc.** · enrollment: 113 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **BIOLOGICAL:** Dose A KER-012
- **BIOLOGICAL:** Dose B KER-012
- **BIOLOGICAL:** Dose C KER-012
- **BIOLOGICAL:** Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks

## Key facts

- **NCT ID:** NCT05975905
- **Lead sponsor:** Keros Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-17
- **Primary completion:** 2025-03-05
- **Final completion:** 2025-03-11
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975905, "A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05975905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*